| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Artificial ligands for growth factor receptors are clinically applicable. We here tried identification of artificial ligands for insulin receptor (IR) using macrocyclic peptide screening, and characterized MET-agonist macrocyclic peptides to establish artificial ligand technology based on macrocyclic peptide. Expression and purification of IR protein with its kinase activity was difficult. Now, purification of IR in nanodiscs is being investigated. We have proved that 1) artificial ligands based on macrocyclic peptide are able to have similar activity compared to natural ligands, 2) partial agonists based on macrocyclic peptide are able to induced biased or selective cellular responses compared to natural ligands, and 3) macrocyclic peptides interact with thier target protein in an unique manner. These results illustrate potential of artificial ligands based on macrocyclic peptides.
|
